Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ofloxacin + itraconazole
- Development stage
- Unknown
- Lead developer
- Gadin Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Floxgin-IT is a fixed-dose combination pharmaceutical product developed and manufactured by Gadin Biotech. It consists of ofloxacin, a fluoroquinolone antibiotic, and itraconazole, a triazole antifungal agent. Ofloxacin functions by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for DNA replication and transcription, thereby exerting bactericidal activity. Itraconazole inhibits the fungal enzyme lanosterol 14-alpha-demethylase (CYP51A1), leading to the depletion of ergosterol and the accumulation of methylated sterol precursors, which disrupts fungal cell membrane integrity. This combination is primarily used to treat mixed infections where both bacterial and fungal pathogens are present or suspected, such as in certain dermatological or pelvic inflammatory conditions.
- Brand names
- Floxgin-IT
- Other names
- Floxgin-IT
02
Targets
Topo IV (Bacterial Topoisomerase IV)CYP51A1 (Sterol 14α-demethylase)CYP5218 (Cytochrome P450 5218)DNA gyrase
Beyond the preview
Go deeper on ofloxacin + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ofloxacin + itraconazole.